Sign in
Not yet taking people in United StatesPhase 2

Tirzepatide for Lung Function and Muscle Health in Overweight Adults With COPD

Tests tirzepatide on muscle and lung function in overweight adults with COPD.

Key facts

Who runs it
The Cleveland Clinic
Where
Cleveland, United StatesSee the site
Trial code
Registry title
GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD
Status
Not yet recruiting
Phase
Phase 2
People taking part
30 people, planned
Started
28 Aug 2026
Expected to end
15 Aug 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tirzepatide
Record updated
5 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 40-80 with COPD who are overweight or obese and used to smoke. It tests whether tirzepatide helps lung function and muscle health.

Age
40 to 80 years
Sex
All sexes can join.
Disease stage
COPD with a post-bronchodilator FEV₁/FVC below 0.70, GOLD stage 1-3 (FEV₁ above 30% predicted).
Earlier treatment
No oral corticosteroids, tamoxifen, high-dose estrogen or testosterone within 6 weeks of enrollment. No current DPP-4 inhibitor. No pulmonary rehabilitation within 2 weeks before enrollment.
Biomarker or test result
BMI of 27 kg/m² or more with at least one weight-related condition (for example prediabetes, high blood pressure, high cholesterol, sleep apnea or heart disease), or BMI of 30-40 kg/m². Former smoker with at least 10 pack-years.

Main reasons for not taking part

  • Type 2 diabetes (HbA1c above 6.5% (48 mmol/mol))
  • Pregnancy or breastfeeding
  • Active cancer, including lung cancer
  • COPD flare-up within 60 days before enrollment
  • History of pancreatitis, or personal or family history of medullary thyroid cancer or MEN2

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age 40-80 years
  • Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁/FVC < 0.70
  • GOLD stage 1-3 COPD (FEV₁ >30% predicted)
  • Former smoker with a smoking history of at least 10 pack-years
  • Body mass index (BMI) ≥27 kg/m² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg/m²
  • Able and willing to provide written informed consent
  • Able to comply with study procedures and follow-up visits

Who cannot take part

  • Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral corticosteroids, tamoxifen, high-dose estrogen, testosterone)
  • Current treatment with a DPP-4 inhibitor
  • COPD exacerbation within 60 days prior to enrollment
  • Participation in pulmonary rehabilitation within 2 weeks prior to enrollment
  • Active malignancy, including lung cancer
  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2 (MEN2)
  • Known hypersensitivity or contraindication to tirzepatide or its components
  • History of pancreatitis
  • Severe gastrointestinal disease that, in the opinion of the investigator, would increase risk from study participation
  • Clinically significant renal impairment
  • Clinically significant gallbladder disease
  • Any medical, psychiatric, or social condition that, in the opinion of the investigators, may interfere with study participation, adherence to study procedures, or participant safety
  • Type 2 diabetes mellitus (HbA1c > 6.5%)
  • Coagulopathy, defined as INR > 1.4 or platelet count <80,000/μL
  • Pregnancy or breastfeeding
  • Significant diabetic retinopathy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 80 years old?

Where in United States

  • Cleveland ClinicCleveland, United StatesContact: Amy Attaway, MDNot yet recruiting

About the trial

What the trial wants to find out

Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation, obesity-related metabolic dysfunction, skeletal muscle impairment, and progressive decline in lung function. While obesity has historically been viewed as protective in COPD, emerging evidence suggests that excess adiposity and adipokine dysregulation, particularly elevated leptin levels, contribute to chronic inflammation, impaired muscle function, and worse clinical outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory, metabolic, and potential muscle-preserving effects beyond weight loss, making them promising therapeutic candidates for COPD.

Read full original descriptionShow less

The GLIMR COPD study is a prospective, randomized, controlled pilot trial designed to evaluate the effects of tirzepatide on lung function, skeletal muscle health, inflammation, and body composition in overweight and obese adults with COPD. Thirty participants will be enrolled at the Cleveland Clinic COPD Center, including 20 participants receiving tirzepatide and 10 age- and sex-matched control participants. Study participants will be followed for 12 months with assessments performed at screening, baseline, 6 months, and 12 months. Tirzepatide-treated participants will undergo standard dose escalation to a maintenance dose of 2.4 mg weekly.

The primary objective is to determine the effect of GLP-1 receptor agonist therapy on skeletal muscle function and physiology over 12 months. Secondary objectives include evaluating changes in body composition, systemic inflammation, adipokine signaling, immune function, pulmonary physiology, physical performance, and treatment tolerability.

The study is built around three mechanistic aims. First, we will characterize the effects of GLP-1 therapy on systemic inflammation and immune dysregulation using longitudinal blood-based proteomic analyses and adipokine measurements, including leptin and adiponectin. Second, we will investigate the impact of GLP-1 therapy on skeletal muscle mitochondrial function and fatty acid oxidation using muscle biopsies obtained at baseline and 12 months, combined with high-resolution respirometry, transcriptomics, metabolomics, and proteomics. Third, we will assess changes in clinical outcomes including lung function, body composition, muscle strength, and physical performance.

Participants will undergo comprehensive phenotyping that includes spirometry, respiratory muscle strength testing, six-minute walk testing, handgrip strength, sit-to-stand testing, body composition assessment, diaphragm ultrasound, and non-contrast CT imaging of the lungs and thighs. Blood samples will be collected for biomarker, proteomic, metabolomic, genomic, and immunologic analyses. Vastus lateralis muscle biopsies will be performed at baseline and study completion to evaluate mitochondrial bioenergetics and molecular pathways associated with muscle remodeling.

Eligible participants will be adults aged 40-80 years with COPD, a smoking history of at least 10 pack-years, and overweight or obesity. Individuals with diabetes, active malignancy, recent COPD exacerbations, contraindications to tirzepatide, or conditions that could interfere with study participation will be excluded.

This pilot study is designed to generate critical mechanistic and clinical data regarding the role of GLP-1 receptor agonists in COPD. Findings will help define the relationships among obesity, adipokine signaling, systemic inflammation, skeletal muscle dysfunction, and lung disease progression, while providing preliminary efficacy estimates to support the design of a future multicenter randomized clinical trial evaluating GLP-1 therapy as a novel treatment strategy for COPD.

The 2 groups in the trial

  • COPD controlNo study treatment, for comparison

    Participants with COPD and overweight or obesity who will not receive tirzepatide and will continue standard clinical care. Participants will complete the same research assessments as the intervention group, including blood collection, pulmonary function testing, physical performance testing, body composition assessments, imaging, and skeletal muscle biopsies, allowing comparison of clinical and biological changes over 12 months.

  • COPD tirzepatide treatmentExisting treatment, for comparison

    Participants with COPD and overweight or obesity will receive once-weekly subcutaneous tirzepatide for 52 weeks in addition to standard clinical care. Participants will undergo longitudinal assessments of lung function, skeletal muscle health, body composition, physical performance, and inflammatory biomarkers to evaluate the effects of tirzepatide on pulmonary and systemic manifestations of COPD.

    Treatment: Tirzepatide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
GLIMR COPD: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD
Plain-language title
Tirzepatide for Lung Function and Muscle Health in Overweight Adults With COPDGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07747805, who can take part
Record updated
5 August 2026